Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Scientists thought Ozempic worked by quieting hunger-promoting brain cells — turns out, it may do the opposite. A new Yale study found that GLP-1 drugs actually activate AgRP neurons (the ones that drive hunger), and those neurons appear essential for sustaining fat loss in mice. The finding reshapes our understanding of these blockbuster drugs and could point the way to even more effective obesity treatments.
Ozempic's surprising brain twist: hunger neurons are actually helping you lose weight
Scientists thought Ozempic worked by quieting the brain's hunger-promoting neurons — but a new Yale study says the opposite may be true. Researchers found that GLP-1 drugs like semaglutide actually activate AgRP neurons, the very cells long associated with driving hunger. Even more striking: when those neurons were genetically silenced in mice, GLP-1 drugs could no longer sustain weight loss — suggesting these "hunger" cells are a key part of the drug's long-term effectiveness.
This builds on earlier NIH research (May 2026) showing that semaglutide triggers variable signaling responses inside appetite-regulating brain cells, helping explain why GLP-1 drugs work differently for different people and why weight loss often plateaus over time.
Key Takeaways:
Why it matters: These findings reshape our understanding of how GLP-1 therapies work in the brain, opening new doors for designing next-generation obesity drugs that are more effective, longer-lasting, or have fewer side effects.
